eHIV Review
Latest Episodes
Harm Reduction Strategies for People Who Inject Drugs
Barriers to HIV screening in people who inject drugs and the impact of improved access to harm reduction services.
PrEP, STIs, & Sexual Health Conversations
STI prevention strategies that should be offered to MSM as part of routine sexual health care.
Clinical Insights: Expanding HIV Testing and Treatment
Different HIV testing options and the potential benefits and limitations of HIV self-testing strategies.
In the Clinic: HIV and Aging
The five "M's" of geriatrics and incorporating them into HIV care.
Increasing PrEP Uptake in Women
Take our post-test to claim CME credits. To read a companion newsletter click here. In the US, among women at high risk for acquiring HIV infection, only around 2% have initiated PrEP. What are the patient, provider,
Increasing PrEP Uptake in PWID
Take our post-test to claim CME credits. To read a companion newsletter click here. People who inject drugs (PWID) are at risk for HIV infection from both sexual- as well as injection-related causes. What can clinicians do to reduce the incidence of in...
Two Drug ART? — Clinical Considerations
In her recent newsletter issue (eHIV Review V5 #1), Dr. Ethel Weld, Assistant Professor of Medicine, Pharmacology and Molecular Sciences at the Johns Hopkins School of Medicine, analyzed the current research about the potential uses of two-drug ART reg...
“U=U” — Clinical Considerations
Volume 4, Issue 12 “U=U” — an Undetectable HIV viral load means Untransmittable HIV virus. In her recent eHIV Newsletter Issue (Vol. 4; No. 11), Dr. Jill Blumenthal from the Division of Infectious Diseases and Global Public Health at the University of...
Clinical Aspects of Improving ART Adherence
Volume 4, Issue 10 In this Issue, Dr. Joyce Jones from the Johns Hopkins University School of Medicine and Dr. Barbara Taylor from the University of Texas Health Science Center at San Antonio analyze recent publications describing evidence-based ART ad...
Clinical Perspective: New AEs from Newer ART
Volume 4, Issue 8 While newer antiviral agents like darunavir and the integrase strand transfer inhibitor (INSTI) dolutegravir have shown great efficacy, recent postmarketing surveillance has identified important adverse effects not found in the clinic...